Brief: Faes Farma Wins Approval Of Bilastine In China, Termination Of Agreement In US

Faes Farma SA

27/06/2023 07:52

June 27 (Reuters) - Faes Farma SA  FAE.MC :
    * APPROVAL OF BILASTINE IN CHINA
    * BILASTINE FOR SYMPTOMATIC TREATMENT OF URTICARIA IN ADULT
AND
ADOLESCENT PATIENTS 12 YEARS OF AGE OR OLDER
    * APPROVAL IN CHINA AWARDED BY CHINESE NATIONAL
PHARMACEUTICAL
ADMINISTRATION (NPMA) FOLLOWING SUCCESSFUL COMPLETION OF LOCAL
CLINICAL STUDIES
    * MENARINI WILL BE RESPONSIBLE FOR PROMOTION AND MARKETING
OF THIS
PRODUCT IN CHINA
    * HIKMA PHARMACEUTICALS HAS DECIDED TO TERMINATE ITS
BILASTINE
LICENSING AGREEMENT WITH FAES FARMA IN US
    * IN US TERMINATION WEIGHED THE LENGTHENING OF DEADLINES IN
REGISTRATION PROCESS WITH US FDA, AS WELL AS FINANCIAL REASONS
GIVEN REQUIRED INVESTMENTS BY HIKMA DURING THIS PROCESS

Source text for Eikon:  ID:nCNMbspmnd 
Further company coverage:  FAE.MC 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))